PYPD News and Press, PolyPid Ltd. From 11/10/21

Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100 for the Pre...

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its propr...

PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its particip...

Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival Company Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential Initiation of ...

PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scie...

PolyPid Ltd. (PYPD) Q2 2021 Earnings Conference Call August 11, 2021 8:30 AM ET Company Participants Bob Yedid – Investor Relations Amir Weisberg – Chief Executive Officer Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer Conference Call Part...

The following slide deck was published by PolyPid Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: PolyPid Ltd. 2021 Q2 - Results - Earnings Call Presentation

•  Recruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery •  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-...

PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief ...

PETAH TIKVA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 20...